Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outpatient (OP) use of lisocabtagene maraleucel (liso-cel) in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Real-world data from the CIBMTR registry

View Full Paper
Ask AI
Bookmark
Share

Authors

KSKonstantinos SdrimasSISami IbrahimiSASairah Ahmed

Discussion

Loading...

Member takes

Overview

Observational study reports high response rates for outpatient liso-cel therapy in relapsed large B-cell lymphoma, indicating strong safety profiles.

Key Points

  • Outpatient treatment with liso-cel shows high overall response rates of 83% in patients with relapsed large B-cell lymphoma.
  • Safety outcomes reveal low rates of adverse events such as cytokine release syndrome and neurotoxicity across treatment settings.
  • This observational study evaluated patients receiving second-line autologous liso-cel therapy in both inpatient and outpatient environments.
  • Results suggest that outpatient administration can maintain efficacy and safety, allowing significant patient hospital avoidance.

Cite This Study

Sdrimas et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de17https://doi.org/10.1182/blood-2025-5482
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world evaluation of health care resource utilization, clinical effectiveness, and safety of lisocabtagene maraleucel and axicabtagene ciloleucel administered in the outpatient (OP) setting for R/R large B-cell lymphoma (LBCL)2025
  2. 2Efficacy and safety of lisocabtagene maraleucel monotherapy in relapsed or refractory large B-cell lymphoma: A systematic review and meta-analysis of clinical trials and real-world studies2025 · 1 citations
  3. 3Efficacy and Safety of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Product-Specific Systematic Review and Meta-Analysis of Clinical Trials and Real-World Studies2026
  4. 4Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM2025 · 1 citations
  5. 5Patient-reported outcomes (PROs) with lisocabtagene maraleucel (liso-cel) in patients with third line or later (3L+) R/R MZL from the Phase 2 TRANSCEND FL study2025 · 1 citations